Molecule to Market: Inside the outsourcing space

Raman’s review of life science in 2022

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with your host, Raman Sehgal, who reflects on the last 12 months in the life science industry.

He covers his 5 key trends from the year including:

• The biotech capital market slowdown and its impact on the outsourcing space
• Sustainability as the hot topic within the sector, from events to company practices
• Businesses operating in an increasingly digital way and what that means for the tech companies supporting them
• The cooling of mergers and acquisitions activity in the life sciences industry
• A reduction of discussion around Covid-19 as it moves into the sector’s rear view
  
  

Come back in 2023 for brand new episodes with great guests, including a special 100th episode celebration. Also, if you’re a previous guest, keep an eye out for an exclusive invitation in your inbox very soon…

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

A blast from the life science past

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with a look back to some of our early guests from the Molecule to Market archive.

Your host, Raman Sehgal, recaps his discussions on the pharmaceutical and biotechnology supply chain with:

• Stefano Console, founder and Senior Advisor at Oriento discussing: founding his business in Switzerland and the fractional management staffing structure that is helping Oriento succeed
• Claire Thompson, founder and CEO of Agility Life Sciences discussing: her career as a footballer and how it has helped her when successfully leading a team
• Jitesh Devendra, Managing Director at Solara Active Pharma Sciences discussing:  why it is crucial to invest time internally to be just as operationally focused as you are strategically focused
• Mary Christian, Senior Vice President, Regulatory at Lyndra Therapeutics discussing: her do’s and don’ts for building new business partnerships

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

Tackling the 3 Big C’s: CDMO Career, Children & Cancer

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Sarah Stevens, SVP and Head of Early Development & Late Stage Commercial Operations at Quotient Sciences.
 
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Sarah, covering:
 
Carving an incredible transatlantic CDMO career in traditionally non-female roles - balancing work, kids and breast cancer.
Words of wisdom for young women developing a career in the outsourcing space, including an appreciation of valuing the female perspective.
The concept of Translational Pharmaceutics® - delivering an agile and integrated offering for accelerating to first-in-human (FIH) clinical trials and optimizing dosage forms for proof-of-concept and beyond.
Potential impact of uncontrollable macro factors and current industry trends on demand for contract services and volunteer recruitment
 
Sarah is the Senior Vice President & Head of Early Development & Late Stage Commercial at Quotient Sciences, with oversight for all global sites and operational functions from early drug development programs through to late stage and commercial manufacturing. Sarah oversees deployment of Quotient’s unique platform for integration, Translational Pharmaceutics, which eliminates white space between these traditionally silo’d drug development areas. Prior to this role, she was the Vice President of Drug Development Sciences, with responsibility for drug development consulting and creation of integrated programs across the organization.
 
Located in Boston, MA, Sarah’s experience spans a range of scientific and leadership roles within the drug product contract development and manufacturing space. Sarah received her PhD in Pharmaceutics from the University of Manchester and her MPharm, Pharmacy from Strathclyde University.
 
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
 
Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

Mystic Miller’s review of ’22 and predictions for ’23

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with independent life sciences consultant Jim Miller. Your host, Raman Sehgal sits down with Jim covering:

• The three biggest macro factors impacting the CDMO space right now
• How CDMOs and CROs are starting to feel the pain of emerging biotech’s funding woes
• What we can learn from the 08-09 financial crash that can help CDMOs/CROs during rockier financial times
• The cooling of M&A and company valuations, and why financial stability may become a more important selection criteria
• Where Jim would place his attention and money if he was running a CDMO...

Jim Miller is a renowned expert in the space and a regular speaker at all the major trade conferences including CPhI WW. He made his name in the sector after founding and growing PharmSource with his wife Judy, an online database on bio/pharmaceutical intelligence, before selling the business to Global Data. Today, he’s an industry consultant and regularly writes for leading industry publications like DCAT and Pharmaceutical Technology.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

Top 5 episodes of all time

As we celebrate the podcast hitting 30,000 downloads and approaching its 100th episode, Raman reflects on the most downloaded episodes with highlights from the top 5.  

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector, diving into the top 5 episodes of all time, featuring:

• JoyL Silva, Pfizer CentreOne discussing: her early career journey and advice, industry trends, and personalized medicines
• Tia Lyles-Williams, LucasPye Bio discussing: equality & diversity, Covid-19’s impact, fundraising and providing opportunities to the next generation  
• Gerry Cox, Velesco Pharma Services discussing: client relationships, starting a new business and his advice 
• Cory Lewis, INCOG BioPharma discussing: acquisitions, turning around a business, and lessons from the franchise model 
• Allan Shaw, Industry Consultant discussing: biotech trends, commonalities & challenges, and the supply chain ecosystem

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! 

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

CPHI 2022 - Trends, challenges & opportunities

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with your host, Raman Sehgal, who discusses emerging trends and challenges for the life sciences sector live from CPHI Frankfurt 2022, with:

• Grainne Hughes, Vice President of Business Support Operations at Almac 
• Christine Fürst, Senior Director Key Account Manager Europe at Vetter Pharma 
• Guido Wallraff, Corporate Business Development Director at Ardena
• Jenny Gattari, CDMO Business Development Lead (North America) at Pfizer CentreOne 
• Brittany Hayes, Director of Global Highly Potent & Oncology Platform at CordenPharma

Listen to this episode to find out more about these companies and gain an insight into the changes and demands they see coming in 2023. They also discuss their experience of CPHI this year, how it compares to last year’s event and what trends they have noticed across their exploration of the Messe. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! 

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

Views from AAPS 2022

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with your host, Raman Sehgal, who discusses future industry trends live from AAPS Boston 2022, with:

• Casey Franklin, VP of Business Development at Alcami

• Umberto Romeo, R&D Manager at Corden Pharma

• Steven Dodd, Executive Director for sales strategy at Icon CRO

• Paul Dickinson, Founder & CSO at Seda Pharmaceutical Development Services

Raman finds out more about the exciting opportunities coming up for these companies in 2023 and beyond, as well as scoring the inside scoop on trends our guests foresee both within their business and the wider industry. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! 

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

The Personalized Medicine Pioneer

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with David Katz, Founder & CSO at Sparrow Pharmaceuticals, Inc.Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with David, covering:

• The contrast of developing new drugs and running clinical trials in a big pharma versus his journey as the founder of a virtual biopharma company.
• What life really looks like and skills you have to develop in a firm developing novel, targeted therapies to address unmet patient needs.
• Some of the options, decisions and pathways to commercialization that a Phase 2 biopharma business has to consider.
• The inspiration, leadership learnings and brand influence of a famous Hollywood character.

Prior to founding Sparrow, David was a pharmaceutical R&D leader at Abbott and AbbVie, where he led clinical development and drug discovery teams, and was a personalized medicine pioneer. David is dedicated to the mentorship of the next generation of life sciences entrepreneurs, currently as an entrepreneur-in-residence at Oregon Health & Science University. He held post-doctoral fellowships in immunology at the Universities of Chicago and Michigan, earned MPhil and PhD degrees in Molecular Biophysics and Biochemistry from Yale University, and is an alumnus of Pomona College (BA, Chemistry). David has published over 50 peer-reviewed scientific papers and in his copious spare time, he is actively involved in new play development and is a glass artist.

Don't forget to subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

 

Inizio’s biotech bromance

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jason McKenna, Global President, and Dean McAlister, Executive Vice President both from Inizio Biotech.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with the dynamic duo, covering:

• A wealth of big pharma learnings for today’s emerging biotechs.
• The (good and bad) impact of the current biotech capital market slowdown on decision-making for outsourced service providers.
• What the future may look like in our space in terms of financing and therapeutic impact.
• Learnings from how to make a business relationship successes from complementary colleagues.

Jason spent the initial part of his career in big pharma, working for AstraZeneca in the US and UK across a variety of marketing, sales and finance roles. He is now the Global President of Inizio’s first enterprise business unit, Inizio Biotech. Jason and his team enable biotech partners to maximize the value of their assets by providing scalable support, through the seamless experience of a single point of coordination. Previously CEO at STEM, an Inizio Advisory company, Jason led the organization through significant scaling and transformation throughout the COVID pandemic.

Dean has over 35 years of biopharma experience across established and startup organizations – including 28 years with AstraZeneca in 16 roles of increasing commercial responsibility, where he led global and regional sales and strategic business development. Dean has built cross-functional teams spanning all therapeutic areas. Following AZ, he grew STEM Healthcare North America from 10 clients to 38 over a five-year period before a sale to UDG. He is also a podcaster, speaker, and published author.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

The Magic of Drug Development

In this special episode of Molecule to Market, we go back inside the global drug development space with Marcelo Bigal, President and CEO, of Ventus Therapeutics, and Versant Venture Partner, who shares his journey from being a neurologist to taking a drug to market when he became part of Teva Pharmaceuticals and now is a CEO.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Marcelo, covering: 

• What it feels like to take a drug from the laboratory to market and what really goes into that process.
• The company’s phenomenal attitude toward patients and how this is exemplified in its drug development. 
• The incredible story of the company he joined and how 14 months after a fundraiser it was acquired by Teva Pharmaceuticals for $825M.
• The current state of the capital market and where future opportunities may lie for the business. 
• The challenging area of drug development in biotechnology over the last three years. 

Marcelo brings more than 13 years of pharma experience with a focus on urology spanning r&d, medical and scientific affairs. He has extensive experience in leading large and small scientific groups, including multiple leadership roles in industry, including the Chief Scientific Officer at Teva as well as Chief Medical Officer at Teva and Purdue. Prior to his work in the pharma sector, Marcelo was a faculty member of the Albert Einstein College of Medicine, Department of Neurology, as well as the director of research at the New England Centre for headache. 

He has authored no fewer than 330 papers in peer-reviewed journals, edited six books in urology and is the recipient of multiple awards and recognitions in the field. Marcelo holds a medical doctorate degree from the College of Medicine at the University of Sao Paulo, Brazil, where he obtained a master’s in science and a PhD in neurosciences. He completed his postdoctoral research at the New England Centre for headache.